

WHAT IS CLAIMED IS:

1. A process for providing a human patient with an agent, comprising:

administering an agent to a human patient by providing the patient with human primary cells genetically engineered to include DNA encoding said agent for expression of said agent *in vivo*.

2. The process of Claim 1 wherein said human primary cells are human primary nucleated blood cells.

3. The process of Claim 2 wherein said cells are leukocytes.

4. The process of Claim 2 wherein said cells are lymphocytes.

5. The process of Claim 2 wherein said cells are T-lymphocytes.

6. The process of Claim 2 wherein the cells are TIL cells.

7. The process of Claim 2 wherein the cells are B-lymphocytes.

8. The process of Claim 1 wherein the cells have been genetically engineered in vitro.

9. The process of Claim 8 wherein said cells have been genetically engineered with a retroviral vector including RNA corresponding to said DNA.

10. The process of Claim 8 wherein the genetically engineered cells are administered to the patient intravenously.

11. The process of Claim 2 wherein the cells are genetically engineered to include DNA encoding a cytokine.

12. The process of Claim 11 wherein the cytokine is TNF.

13. The process of Claim 11 wherein the cytokine is an interleukin.

~~14. The process of Claim 1 wherein the agent is a therapeutic agent.~~

~~15. Human primary cells genetically engineered to include DNA encoding an agent.~~

~~16. The cells of Claim 15 wherein the cells are human primary nucleated blood cells.~~

~~17. The cells of Claim 16 wherein the cells are leukocytes.~~

~~18. The cells of Claim 16 wherein said cells are lymphocytes.~~

~~19. The cells of Claim 16 wherein the cells are T lymphocytes.~~

~~20. The cells of Claim 16 wherein said cells are TIL cells.~~

~~21. The cells of Claim 16 wherein said cells are B-lymphocytes.~~

~~22. The cells of Claim 15 wherein the agent is a therapeutic agent.~~

~~23. The cells of Claim 22 wherein the cells have been genetically engineered with a retroviral vector which includes RNA corresponding to said DNA.~~

~~24. A composition for administration to a human patient comprising:~~

~~the cells of Claim 15 and a pharmaceutically acceptable carrier.~~

~~25. The process of Claim 1 wherein said human primary cells are human primary tumor cells.~~

~~26. The cells of Claim 15 wherein the cells are human primary tumor cells.~~

insert

a1

insert

a2